BridgeMD
New treatment option for Lymphoma (Non-Hodgkin's Lymphoma)
Official title A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
ClinicalTrials.gov ID: NCT07628738
What this study is testing
- What it's testing
- This study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nasal-type NK/T-cell lymphoma that has achieved complete remission after chemotherapy.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- The patient voluntarily agrees to participate in this study and signs the informed consent form.
- Age ≥ 18 years and ≤ 75 years.
- Pathologically confirmed diagnosis of nasal-type NK/T-cell lymphoma.
- Clinical stage I-II disease confirmed by PET-CT or MRI.
- The lymphoma has been treated with an asparaginase-based chemotherapy regimen.
You likely can't join if
- A previous or concurrent diagnosis of another malignancy, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, or...
- Presence of severe medical conditions, or concomitant diseases or situations that may affect the patient's eligibility for enrollment or compromise...
- Pregnant or breastfeeding women.
- Presence of active mental disorders or other psychiatric conditions that may affect the patient's ability to sign the informed consent form or to...
- Patients deemed by the investigator to have poor compliance.
- Distant metastasis confirmed by pathology or imaging.
See the full eligibility criteria
- The patient voluntarily agrees to participate in this study and signs the informed consent form.
- Age ≥ 18 years and ≤ 75 years.
- Pathologically confirmed diagnosis of nasal-type NK/T-cell lymphoma.
- Clinical stage I-II disease confirmed by PET-CT or MRI.
- The lymphoma has been treated with an asparaginase-based chemotherapy regimen.
- Presence of 0-1 prognostic risk factors (risk factors: age \> 60 years, ECOG score ≥ 2, elevated LDH, elevated PTI, stage II).
- Imaging assessment shows complete clinical remission after chemotherapy.
- ECOG-PS score of 0-1.
- Expected survival of ≥ 12 months.
- Normal function of major organs, meeting the following criteria:
- Hematology: absolute neutrophil count ≥ 1.5 × 10⁹/L; platelet count ≥ 80 × 10⁹/L; hemoglobin ≥ 80 g/L.
- Biochemistry: total bilirubin \ 50 mL/min.
- Female people of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use highly effective contraception during the study period and for 120 days...
- A previous or concurrent diagnosis of another malignancy, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the breast.
- Presence of severe medical conditions, or concomitant diseases or situations that may affect the patient's eligibility for enrollment or compromise safety during the study period.
- Pregnant or breastfeeding women.
- Presence of active mental disorders or other psychiatric conditions that may affect the patient's ability to sign the informed consent form or to comprehend the study information.
- Patients deemed by the investigator to have poor compliance.
- Distant metastasis confirmed by pathology or imaging.
- As judged by the investigator, the patient has other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other serious diseases (including mental...
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.